X

Drug Profile

Research Programme: neuropathic pain therapy - NeuroSolutions/Nxera Pharma

Alternative Names: NSL-036

Latest Information Update: 02 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroSolutions; Sosei
Developer NeuroSolutions; Nxera Pharma
Class
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Neuropathic pain

Most Recent Events

31 Mar 2024 Sosei Heptares is now called Nxera Pharma
03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
16 Aug 2012 Discontinued - Preclinical for Neuropathic pain in Japan (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com